Literature DB >> 12481427

Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells.

Toshihiko Takenobu1, Kazuhito Tomizawa, Masayuki Matsushita, Sheng-Tian Li, Akiyoshi Moriwaki, Yun-Fei Lu, Hideki Matsui.   

Abstract

Recent studies suggest that several proteins can transverse biological membranes through protein transduction. The protein transduction domains of these proteins, 10-16 residues long, have been identified as critical domains for the protein transduction. Poly-arginine peptide also has the ability of protein transduction. Here, we show that the protein delivery system using 11 poly-arginine peptides (11R) is a powerful tool for the transduction of the biologically active tumor suppressor protein, p53, to suppress the proliferation of oral cancer cells. The 11R-fused p53 proteins (11R-p53) effectively penetrated across the plasma membrane of the cancer cells and translocated into the nucleus. The proteins induced the activity of the p21/WAF promoter and inhibited the proliferation of human oral cancer cells, in which the p53 gene was mutated. The effect was equivalent to that of the adenovirus-mediated p53 gene transduction system. Moreover, 11R-p53 enhanced the cisplatin-dependent induction of apoptosis of the cells. These data suggest that this protein transduction method may become a promising cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12481427

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  20 in total

1.  Protein therapy using heme-oxygenase-1 fused to a polyarginine transduction domain attenuates cerebral vasospasm after experimental subarachnoid hemorrhage.

Authors:  Tomoyuki Ogawa; Daniel Hänggi; Yumei Wu; Hiroyuki Michiue; Kazuhito Tomizawa; Shigeki Ono; Hideki Matsui; Isao Date; Hans-Jakob Steiger
Journal:  J Cereb Blood Flow Metab       Date:  2011-06-08       Impact factor: 6.200

2.  Peptide HIV-1 integrase inhibitors from HIV-1 gene products.

Authors:  Shintaro Suzuki; Emiko Urano; Chie Hashimoto; Hiroshi Tsutsumi; Toru Nakahara; Tomohiro Tanaka; Yuta Nakanishi; Kasthuraiah Maddali; Yan Han; Makiko Hamatake; Kosuke Miyauchi; Yves Pommier; John A Beutler; Wataru Sugiura; Hideyoshi Fuji; Tyuji Hoshino; Kyoko Itotani; Wataru Nomura; Tetsuo Narumi; Naoki Yamamoto; Jun A Komano; Hirokazu Tamamura
Journal:  J Med Chem       Date:  2010-07-22       Impact factor: 7.446

3.  Trans-membrane peptide therapy for malignant glioma by use of a peptide derived from the MDM2 binding site of p53.

Authors:  Sachiko Yamada; Hiroshi Kanno; Nobutaka Kawahara
Journal:  J Neurooncol       Date:  2012-04-18       Impact factor: 4.130

4.  Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5.

Authors:  Tai-Guang Jin; Alexei Kurakin; Nordine Benhaga; Karon Abe; Mehrdad Mohseni; Ferry Sandra; Keli Song; Brian K Kay; Roya Khosravi-Far
Journal:  J Biol Chem       Date:  2004-10-14       Impact factor: 5.157

Review 5.  Why does cytotoxic chemotherapy cure only some cancers?

Authors:  Philip Savage; Justin Stebbing; Mark Bower; Tim Crook
Journal:  Nat Clin Pract Oncol       Date:  2008-11-04

6.  Regulation of the endogenous VEGF-A gene by exogenous designed regulatory proteins.

Authors:  Kiyoshi Tachikawa; Oliver Schröder; Gerhard Frey; Steven P Briggs; Takashi Sera
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-08       Impact factor: 11.205

7.  Effects of dendritic cells transfected with full-length wild-type p53 and stimulated by gastric cancer lysates on immune response.

Authors:  Hua-Wen Sun; Qi-Bing Tang; Yong-Jun Cheng; Sheng-Qian Zou
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

Review 8.  [The use of p53 as a tool for human cancer therapy].

Authors:  V P Almazov; D V Kochetkov; P M Chumakov
Journal:  Mol Biol (Mosk)       Date:  2007 Nov-Dec

9.  Inhibition of cell proliferation, migration and invasion by a glioma-targeted fusion protein combining the p53 C terminus and MDM2-binding domain.

Authors:  Jiawen Yu; Meihua Guo; Ting Wang; Xiang Li; Dan Wang; Xinying Wang; Qian Zhang; Liang Wang; Yang Zhang; Chunhui Zhao; Bin Feng
Journal:  Cell Prolif       Date:  2016-02-03       Impact factor: 6.831

Review 10.  Cell-Penetrating Peptides: Applications in Tumor Diagnosis and Therapeutics.

Authors:  Jeffrey Stiltner; Kayla McCandless; Maliha Zahid
Journal:  Pharmaceutics       Date:  2021-06-15       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.